ZIOPHARM Oncology, Inc. total revenue, net income and dynamics of changes in Euro today
ZIOPHARM Oncology, Inc. current income in Euro. The dynamics of net revenue of ZIOPHARM Oncology, Inc. rose. The change amounted to 0 €. The dynamics of net revenue is shown in comparison with the previous report. These are the main financial indicators of ZIOPHARM Oncology, Inc.. The financial report schedule from 31/12/2018 to 31/03/2021 is available online. ZIOPHARM Oncology, Inc. financial report on the graph shows the dynamics of assets. The value of all ZIOPHARM Oncology, Inc. assets on the graph is shown in green.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
31/03/2021
0 €
-
-20 012 134.61 €
-
31/12/2020
0 €
-
-21 143 004.98 €
-
30/09/2020
0 €
-
-18 861 766.48 €
-
30/06/2020
0 €
-
-17 265 735.14 €
-
30/09/2019
0 €
-
-68 702 696.14 €
-
30/06/2019
0 €
-
-13 574 158.30 €
-
31/03/2019
0 €
-
-12 472 998.81 €
-
31/12/2018
0 €
-
-11 588 171.67 €
-
Show:
to
ZIOPHARM Oncology, Inc. financial report charts
Dates of ZIOPHARM Oncology, Inc. finance reports: 31/12/2018, 31/12/2020, 31/03/2021. Dates and dates of financial statements are established by the laws of the country where the company operates. The latest date of the financial report of ZIOPHARM Oncology, Inc. is 31/03/2021. Gross profit ZIOPHARM Oncology, Inc. is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit ZIOPHARM Oncology, Inc. is -13 336 000 €
ZIOPHARM Oncology, Inc. quarterly report dates
Cost of revenue ZIOPHARM Oncology, Inc. is the total cost of producing and distributing of products and services of a company. Cost of revenue ZIOPHARM Oncology, Inc. is 13 336 000 € Operating income ZIOPHARM Oncology, Inc. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income ZIOPHARM Oncology, Inc. is -20 963 000 € Net income ZIOPHARM Oncology, Inc. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income ZIOPHARM Oncology, Inc. is -21 554 000 €
Current assets ZIOPHARM Oncology, Inc. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets ZIOPHARM Oncology, Inc. is 112 710 000 € Total assets ZIOPHARM Oncology, Inc. refers to the total amount of assets owned by a person or entity. Total assets ZIOPHARM Oncology, Inc. is 128 472 000 € Current cash ZIOPHARM Oncology, Inc. - the sum of all of the cash a company has on the date of report. Current cash ZIOPHARM Oncology, Inc. is 100 056 000 €
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-12 382 009.24 €
-12 971 584.52 €
-12 968 799.12 €
-11 188 931.72 €
-8 022 866.07 €
-9 282 793.07 €
-8 798 134.34 €
-7 612 484.54 €
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
12 382 009.24 €
12 971 584.52 €
12 968 799.12 €
11 188 931.72 €
8 022 866.07 €
9 282 793.07 €
8 798 134.34 €
7 612 484.54 €
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
-
-
-
-
-
-
-
-
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
-
-
-
-
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-19 463 411.80 €
-21 144 861.91 €
-18 867 337.27 €
-17 275 019.79 €
-12 485 997.32 €
-13 697 644.15 €
-12 646 621.77 €
-11 849 070.33 €
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-20 012 134.61 €
-21 143 004.98 €
-18 861 766.48 €
-17 265 735.14 €
-68 702 696.14 €
-13 574 158.30 €
-12 472 998.81 €
-11 588 171.67 €
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
-
-
-
-
8 022 866.07 €
8 022 866.07 €
8 022 866.07 €
8 022 866.07 €
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
19 463 411.80 €
21 144 861.91 €
18 867 337.27 €
17 275 019.79 €
12 485 997.32 €
13 697 644.15 €
12 646 621.77 €
11 849 070.33 €
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
104 647 290.15 €
121 247 315.89 €
143 977 996.02 €
160 787 854.84 €
107 329 625.54 €
61 147 776.44 €
68 792 757.25 €
78 255 672.53 €
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
119 281 755.48 €
135 876 210.43 €
154 026 772.71 €
168 682 592.74 €
109 511 518.29 €
67 938 569.45 €
77 529 612.90 €
88 251 526.72 €
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
92 898 494.04 €
106 837 539.09 €
125 780 082.02 €
142 538 875.27 €
82 093 946.84 €
40 446 720.80 €
47 803 877.46 €
57 313 215.99 €
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
10 376 524.84 €
9 656 036 €
7 742 469.64 €
8 804 633.60 €
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
10 977 241.70 €
10 378 381.77 €
8 622 654.46 €
8 808 347.46 €
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
10.02 %
15.28 %
11.12 %
9.98 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
98 083 971.07 €
115 112 947.63 €
134 551 290.87 €
151 724 179.51 €
98 534 276.59 €
57 560 187.68 €
68 906 958.44 €
79 443 179.26 €
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-10 145 337.06 €
-7 508 496.46 €
-9 500 053.88 €
-10 973 527.84 €
Last revenue report of ZIOPHARM Oncology, Inc. was 31/03/2021. According to last financial report total revenue in ZIOPHARM Oncology, Inc. was 0 Euro and changed by 0% since last year. Net income in ZIOPHARM Oncology, Inc. was -20 012 134.61 € in last quartal, net income changes to 0%.
ZIOPHARM Oncology, Inc. stocks data
WEK.F stock price
ZIOPHARM Oncology, Inc. stock price today, WEK.F stock quote.
